The Husni lab’s ongoing work in TNFR signaling in psoriatic disease has revealed that PRMT5 plays a critical role in TNF-α induction of gene expression at varying levels.
Using patient reported outcomes to measure low states of disease activity may be very useful in the establishment of comprehensive treatment targets in psoriatic arthritis.
Co-management clinics yield improved patient outcomes and increased opportunities for research and education. In this article, rheumatologist Elaine Husni, MD, MPH, and dermatologist Anthony Fernandez, MD, PhD, discuss their new shared clinic.
Research reveals a defect in myosin binding to TNFR2-M196R causes TNF-independent proinflammatory activity. The ability to genotype this polymorphism should help to predict inadequate responders to anti-TNF therapies early on, and allowing a personalized approach to the treatment of rheumatoid and psoriatic diseases.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Is it idiopathic psoriasis or TNFi-induced psoriasis? A new study finds histological differences between these two types of psoriatic lesions that impact treatment.
Clinical disease activity measures provide only a limited assessment of health domains that are important to patients, which may lead to under- or over-treatment and patient dissatisfaction. Rheumatologist Elaine Husni, MD, MPH, explains the findings of her recent study, and why it’s so important for clinicians to listen carefully when patients report symptoms.
Preclinical models suggest that specific blockade of TNFR2 may significantly reduce inflammation and ameliorate signs of psoriatic diseases, while maintaining normal immune response in the host, including the ability to combat infection and cancer. In this article, M. Elaine Husni, MD, MPH, highlights her latest research and discusses her plans to use her new R01 grant to continue her translational work.
The DISCONNECT study assessed differing perceptions among patients and physician specialists regarding symptoms associated with psoriatic disease.
A recent Cleveland Clinic study determined that paraoxonase-1 (PON1) has the potential for use as a biomarker for cardiac risk in psoriatic disease.
With a wealth of assessment tools at the rheumatologist’s disposal, a collaborative approach involving primary care, dermatology and behavioral health will allow the best assessment and treatment of psychosocial burden in patients with PsA.